Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 243
- Registration Number
- NCT02715531
- Locations
- 🇺🇸
Stanford Cancer Institute; Hematology, Palo Alto, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT02694718
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
- Conditions
- Rectal Adenocarcinoma
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 50
- Registration Number
- NCT02688712
- Locations
- 🇺🇸
Providence Cancer Center, Portland, Oregon, United States
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
- Conditions
- Adenocarcinoma of the StomachAdenocarcinoma of the OesophagusAdenocarcinoma of the Gastro-oesophageal Junction
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 924
- Registration Number
- NCT02678182
- Locations
- 🇬🇧
The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Sutton, United Kingdom
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT02669173
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Target Recruit Count
- 300
- Registration Number
- NCT02656589
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 120
- Registration Number
- NCT02633176
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇨🇳Tongji Hospital,Tongji Medical College of Huazhong University of Science ＆ Technology, Wuhan, Hubei, China
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
- Conditions
- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
- Interventions
- Drug: OxaliplatinDrug: AvelumabDrug: 5-FluorouracilDrug: LeucovorinDrug: CapecitabineOther: Best supportive care
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2022-06-09
- Target Recruit Count
- 499
- Registration Number
- NCT02625610
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇫🇷Centre Georges François Leclerc, Dijon cedex, Côte-d'Or, France
Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Tianshu Liu
- Target Recruit Count
- 200
- Registration Number
- NCT02623153
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 612
- Registration Number
- NCT02614794
- Locations
- 🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Paris Regional Medical Center / US Oncology, Paris, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.